Network Insights Methodology Whitepaper Get Access

Merck

ORG Health Care / Pharmaceuticals Momentum 21.1ML Momentum Score (0-100). Weighted composite of 9 features: mention velocity, article breadth, relationship density, deal context, recency, market cap, enrichment completeness, mention concentration, entity type. CRITICALPSI regime classification. QUIET (<0.3): baseline activity. NORMAL (0.3-0.5): typical deal flow. ELEVATED (0.5-0.7): above-average signals. HIGH (0.7-0.85): significant activity. EXTREME (>0.85): exceptional signal concentration. Primary: Spectral Shift

$59.3B revenue (2025), Kenilworth pharma cuts Zepatier (Hepatitis C) prices steeply amid competition from Gilead's fixed-dose regimens. Multiple signal reports on price reduction and comparative trial performance losses.

Pricing pressure on Hepatitis C portfolio; recent clinical trial outcomes with competitor Gilead
-0.06
PSI ScorePlocamium Signal Index - composite z-score from 5 orthogonal signals: news frequency, targeted sentiment, graph centrality, regulatory filings, and clinical trial activity.
21.1
MomentumML Momentum Score (0-100). Weighted composite of 9 features including mention velocity, article breadth, deal context, and relationship density. Retrained weekly.
1%
ConfidenceSignal confidence - percentage of PSI sub-signals with sufficient data (30+ observations). Higher confidence means the PSI score is based on more complete data.
7
ConnectionsDegree centrality - number of unique entities this entity co-occurs with in news signals and articles. Higher = more connected in the intelligence network.
Merck is graph community structure is reorganizing around this entity — relationship patterns are changing (primary driver: Spectral Shift).
Connected Entities
Pfizer Novartis PlocamiumAI FDA AstraZeneca China India Eli Lilly Roche European Union HHS Robert F. Kennedy Jr. Paris Mumbai Bloomberg
Watch This Entity
PSI Intelligence
30-Day Trend
2026-05-18 2026-06-17 10 0 Degree Mentions
Signal Decomposition
Attention Cascade
3.332
Narrative Drift
0.000
Spectral Shift
429.102
Sentiment-Momentum Divergence
0.000
Source Concentration
0.919
Signal
Merck is graph community structure is reorganizing around this entity — relationship patterns are changing (primary driver: Spectral Shift).
Driver
Ranked #42 of 87 in Health Care — in line with sector peers. PSI stable vs yesterday (-0.12).
Action
Baseline conditions. Continue standard monitoring cadence.
Peer Comparison
42 of 87
Sector Rank
+0.07
Peer Z-Score
52%
Sector Percentile
Network Analysis
7 Degree Centrality
Ego Network (top connections)
Pfizer (weight 94.0)Novartis (weight 91.0)PlocamiumAI (weight 10.0)FDA (weight 8.0)AstraZeneca (weight 7.0)China (weight 7.0)India (weight 4.0)Eli Lilly (weight 4.0) PfizerNovartisPlocamiumAIFDAAstraZenecaChinaIndiaEli Lilly Merck (degree 7) Merck
Centrality History
2026-05-18 2026-06-17 10 0 Degree Mentions
EntityWeight StatusFirst Seen
Pfizer 94 STRENGTHENED
Novartis 91 NEW
PlocamiumAI 10 NEW
FDA 8 STRENGTHENED
AstraZeneca 7 NEW
China 7 STABLE
India 4 STABLE
Eli Lilly 4 NEW
Roche 3 NEW
European Union 3 STABLE
HHS 2 STABLE
Robert F. Kennedy Jr. 2 NEW
Paris 2 NEW
Mumbai 2 NEW
Bloomberg 2 STABLE
New Jersey 2 NEW
Article Coverage (0)
DateLaneTitle
No Plocamium-authored coverage yet. This entity surfaces in upstream signals (news, filings, trials) but has not yet been a primary subject of a published article. Watch this entity to be alerted when one is published.

Request Access

Full PSI intelligence, network analysis, EDGAR filings, and predicted links require an access token.

Data as of 2026-06-17 ← Intelligence Network